News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ERT Named Preferred Provider For IVR Administration Of Key Quality Of Life Assessments


2/18/2014 9:25:32 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

PHILADELPHIA, PA – February 18, 2014 –– ERT, a leading global solution provider for high-quality patient safety and efficacy endpoint data collection, today announced it has been named a preferred provider for the administration of the EuroQol Group’s EQ-5D patient reported outcome (PRO) assessment. Specifically, VIAPhone, ERT’s Interactive Voice Response (IVR) system, has been approved to capture both the EQ-5D-3L and the EQ-5D-5L versions of the quality of life assessment.

The EQ-5D is a commonly used, standardized instrument for measuring health outcomes during the clinical development of new medical products. Both the EQ-5D-3L and EQ-5D-5L versions address health-related quality of life on the same five dimensions – mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Users of the EQ-5D-3L can choose from three levels of severity, whereas users of the EQ-5D-5L can choose from five different severity levels.

The EuroQol Group – the copyright owner of the scale – awarded preferred provider status to ERT based on ERT’s established process for ensuring compliant and high-quality electronic implementations of this scale.

“We are pleased that ERT can now offer its customers a reliable option for capturing important health outcomes information via IVR administration of the EQ-5D,” said Gerben Bakker, User Support Officer, EuroQol Group. “This offering will enable biopharmaceutical researchers to evaluate whether patients’ health states are impacted by new medical treatments.”

VIAPhone is one of ERT’s multiple electronic solutions that improve the collection of clinical outcome assessment (COA) data in clinical research. VIAPhone offers significant advantages over paper-and-pencil administration of the scale, including improvements in patient compliance, data quality and increased trial efficiencies.

“Being named a preferred provider verifies that the scientific foundation upon which our electronic COA solutions are built meets the high standards set by EuroQol,” said Bob Young, Executive Vice President, COA Solutions, ERT. “We are pleased to receive this recognition and look forward to continuing our long-term relationship with the EuroQol Group.” For more information on VIAPhone and its applications for clinical research, visit https://www.ert.com/clinical/clinical-endpoints/outcomes-assessments.

About ERT

ERT (www.ert.com) is a leading provider of high-quality patient safety and efficacy data collection solutions for use in clinical drug development and healthcare settings. ERT delivers the most widely deployed solutions in centralized cardiac safety, respiratory services, suicide risk assessment and Clinical Outcome Assessments (COAs) – which includes patient, clinician and observer reported outcomes. By efficiently integrating these solutions through a system built upon a scientific and regulatory foundation, ERT is able to increase the accuracy and reliability of patient data that it collects, analyzes and delivers. ERT is a global organization with headquarters in Philadelphia, Pa. and offices throughout the U.S., U.K., Japan and Germany.

About EuroQol Group

Established in 1987, the EuroQol Group first met to test the feasibility of jointly developing a standardized non disease specific instrument for describing and valuing health-related quality of life.

The Group comprises a network of international, multilingual, multidisciplinary researchers, originally from seven centres in England, Finland, the Netherlands, Norway and Sweden.

The process of shared development, local experimentation and lively discussion resulted in EQ-5D, a measure generating a single index value for health status with considerable potential for use in health care evaluation.

EQ-5D was initially developed simultaneously in Dutch, English, Finnish, Norwegian and Swedish. It is now widely used in many countries around the world and has been translated into most major languages with the Group closely monitoring the process.

The EuroQol Group aims to improve decisions about health and health care throughout the world by developing, promoting and supporting the use of instruments with the widest possible applicability for the measurement and valuation of health.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
ERT
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES